NCT02280902View on ClinicalTrials.gov

Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases

CompletedOBSERVATIONAL
Enrollment

72

Participants

Timeline

Start Date

February 16, 2016

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions
Immunologic and Inflammatory Diseases
Interventions
BIOLOGICAL

Blood samples

Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.

Trial Locations (7)

31300

service Médecine Interne - CHU de Toulouse - Hôpital Purpan (5), Toulouse

33075

Service de Médecine Interne et maladies Infectieuses - Hôpital Saint-André, Bordeaux

47923

Service de Médecine Interne - CH d'Agen, Agen

64000

Service de Médecine Interne - CH de Pau, Pau

87042

Service de Médecine Interne - CHU de Limoges, Limoges

Unknown

service de médecine interne - CH de Libourne, Libourne

service Médecine Interne - CHU de Toulouse - Hôpital Purpan (7), Toulouse

All Listed Sponsors
collaborator

Ministry for Health and Solidarity, France

OTHER_GOV

lead

University Hospital, Bordeaux

OTHER

NCT02280902 - Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases | Biotech Hunter | Biotech Hunter